Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)
Avalo Therapeutics (AVTX) reported Change in Receivables of -$387000.0 for Q4 2024, up 72.4% on a YoY basis from -$224482.4 in Q1 2024, and down 140.1% quarter-over-quarter from $965000.0 in Q3 2024.
Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024) Analysis & Trends
Avalo Therapeutics has reported Change in Receivables for 8 years, with the latest figure at -$387000.0 in Q4 2024.
- For the quarter ending Q4 2024, Change in Receivables rose 72.4% year-over-year to -$387000.0; the trailing twelve-month figure through Dec 2024 stood at $475000.0 (up 126.64% YoY), and the FY2024 full-year result was $475000.0, up 126.64% from the prior year.
- Change in Receivables for Q4 2024 stood at -$387000.0, down from $965000.0 in the prior quarter.
- The five-year high for Change in Receivables was $3.7 million in Q3 2020, with the low at -$2.7 million in Q3 2021.
- Historically, Change in Receivables has averaged $63500.0 across 5 years, with a median of -$112000.0 in 2022.
- The largest YoY upside for Change in Receivables was 1022.33% in 2020 against a maximum downside of 1577.66% in 2020.
- Avalo Therapeutics' Change in Receivables stood at -$2.1 million in 2020, then surged by 209.44% to $2.3 million in 2021, then slumped by 39.95% to $1.4 million in 2022, then slumped by 202.71% to -$1.4 million in 2023, then soared by 72.4% to -$387000.0 in 2024.
- The last three Change in Receivables figures came in at -$387000.0 (Q4 2024), $965000.0 (Q3 2024), and -$2000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -387,000.00 |
| Dec 31, 2024 | -387,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -101,000.00 |
| Mar 31, 2024 | -101,000.00 |
| Dec 31, 2023 | -1.40 Mn |
| Dec 31, 2023 | -1.40 Mn |
| Sep 30, 2023 | -419,000.00 |
| Sep 30, 2023 | -419,000.00 |
| Jun 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | -1.91 Mn |
| Sep 30, 2022 | -1.91 Mn |